Navigation Links
Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA

PARSIPPANY, N.J. and BETHLEHEM, Pa., June 25, 2012 /PRNewswire/ -- Today, Daiichi Sankyo, Inc. received U.S. Food and Drug Administration (FDA) approval to package product at its first United States-based packaging facility located in Bethlehem, PA. With this approval, the Company expands its global supply chain capability, helping to ensure the supply of medicine to U.S. physicians and their patients.

At this time, the 140,000 square foot facility will package some of the Company's portfolio of marketed products for cardiovascular and metabolic therapies including treatments for hypertension and heart disease, diabetes and hyperlipidemia. Looking ahead, the facility could assume additional responsibilities related to clinical trial materials and perform formulation and analytical testing for select products.

"From facility and process design to quality control and personnel flow, we incorporated leading-edge technology in the design and development of the Bethlehem facility," said Jeff Lane, Vice President, Operations, Daiichi Sankyo, Inc. "The commissioning of this facility is a major milestone for our U.S. organization and augments our ability to manufacture and distribute quality medicines."

The plant currently employs approximately 39 full-time employees and will continue to add employees until realizing its full operational goals. Responsibilities range from Line Operators and Material Handlers to Project Engineers and Quality Specialists. Daiichi Sankyo worked with a number of regional and local business leaders and organizations, including the Governor's Action Team, Lehigh Valley Economic Development Corporation, Northampton County and City of Bethlehem to make this milestone possible.

Lane added that by expanding the Company's business operations to include manufacturing in the U.S., the Company is helping to minimize risks associated with product supply, and is able to gain greater control over the life cycle of its products, from research and development through packaging and distribution.

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the Daiichi Sankyo Group.  For more information on Daiichi Sankyo, Inc., please visit

SOURCE Daiichi Sankyo
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. China Biologic Receives SFDA Manufacturing Approval Certificate for Human Coagulation Factor VIII
2. Bluechiip Receives First Sales Order from ATCC after Completion of Successful Pilot Trial
3. Surefire Medical Receives FDA Clearance For High-Flow Microcatheter
4. Tetra Discovery Partners Receives Major NIH Award To Develop New Alzheimers Drug
5. Celladon Corporation Receives Notice of Allowance from European Patent Office
6. GSK Receives FDA Approval for MenHibrix®
7. Cardiosolutions, Inc. Receives FDA 510(k) Clearance for Dexterity™ Steerable Introducer
8. Cochlear Americas Receives FDA Approval of the Worlds Thinnest, Full Length Electrode for Cochlear Implantation
9. CSL Behring Receives FDA Orphan Drug Designation for rIX-FP, a Novel Therapy in Development to Treat Congenital Factor IX Deficiency (Hemophilia B)
10. PharmaNet/i3 Receives Distinguished Partner Award from the US Chinese Anti-Cancer Association
11. ViewRay Receives FDA 510(k) Clearance for MRI-Guided Radiation Therapy System
Post Your Comments:
(Date:6/23/2016)... June 23, 2016 Bracket , a leading ... next generation clinical outcomes platform, Bracket eCOA (SM) 6.0, ... June 26 – 30, 2016 in Philadelphia ... Clinical Outcome Assessment product of its kind to fully integrate ... Bracket eCOA 6.0 is a flexible platform for electronic ...
(Date:6/23/2016)... Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment ... Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... General Manager of Astellas Farma Colombia ... ...
(Date:6/23/2016)... 23, 2016 The vast majority of dialysis ... facility.  Treatments are usually 3 times a week, with ... including travel time, equipment preparation and wait time.  This ... grueling for patients who are elderly and frail.  Many ... and rehabilitation centers for some duration of time. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due ... up a new, often overlooked aspect of head lice: the parasite’s ability to live away ... a common occurrence, but a necessary one in the event that lice have simply gotten ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
Breaking Medicine News(10 mins):